1. Xu QL#, Hua X#, Li BB#, Jiang B, Jin JJ, Wu RP, Gu Y, Xu H, Cheng QP, Zhu SH, Zhang F, Lv TF*, Song Y*.Intrinsic STING of CD8+T cells regulates self-metabolic reprogramming and memory to exert anti-tumor effects.Cell Commun Signal. 2025 Feb 19;23(1):99.  ( 8.9;2区)

2. Xu H#, Shen KK#, Jiang B, Xu QL, Li BB, Ke ZM, Cheng QP, Zhu SH, Wang D, Song Y, Lv TF. VISTA expressed on tumor cells is regulated by m6A and influences immune microenvironment through STAT3/CCL22 in NSCLC. J Transl Med. 2025 Oct 2;23(1):1043. doi: 10.1186/s12967-025-06818-3.   (7.5;2区)

3. Liu JX#, Wei LY #, Miao QY #, Zhan ST, Chen PL, Liu W, Cao L, Wang D, Liu HB, Yin J, Song Y, Ye MX*, Lv TF *. MDM2 drives resistance to Osimertinib by contextually disrupting FBW7-mediated destruction of MCL-1 protein in EGFR mutant NSCLC.Exp Clin Cancer Res,2024 Nov 15;43(1):302. (11.4;医学1区)

4.  Hua X#, Xu QL#, Wu RP #, Sun W, Gu YL, Zhu SH, Liu X, Lv TF *, Song Y*. ALKBH5 promotes non-small cell lung cancer progression and susceptibility to anti-PD-L1 therapy by modulating interactions between tumor and macrophages. J Exp Clin Cancer Res. 2024 Jun 14;43(1):164.   （11.3；医学1区）

5.  Lv LT #, Miao Q#, Zhan ST, Chen PL, Liu W, Lv JW, Yan WJ, Wang D, Liu HB, Yin J, Feng J, Song Y, Ye MX *, Lv TF*.LKB1 dictates sensitivity to immunotherapy through Skp2-mediated ubiquitination of PD-L1 protein in non-small cell lung cancer.J Immunother Cancer,2024 Dec 18;12(12):e009444. (10.3;医学1区)

6.  Lv JW, Chen JY, Song YY, Yao YW, Wu GN, Yuan DM, Gu XL, Li X, Xu CW, Zhou BL, Ye MX, Lv TF*, Wang D*, Song Y*.Co-Delivery of VEGF siRNA and THPP via Metal–Organic Framework Reverses Cisplatin-Resistant Non-Small Cell Lung Cancer and Inhibits Metastasis through a MUC4 Regulating Mechanism. ACS Appl Mater Interfaces . 2024 Oct 23;16(42):56910-56925.   ( 8.3;医学2区)

7.  Liu JX #, Wei LY #, Hu N #, Wang D, Ni J, Zhang S, Liu HB, Lv TF, Yin J, Ye MX *, Song Y *.    FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer. J Immunother Cancer.2022 Sep;10(9):e005116.  (12.469;1区)

8.  Wang YM, Li CL, Wang ZM, Wang ZF, Wu RP, Wu Y *, Song Y *, Liu HB*.Comparison between immunotherapy efficacy in early non-small cell lung cancer and advanced non-small cell lung cancer: a systematic review.BMC Med.2022 Nov 7;20(1):426.    (11.15;1区)

9.  Liu JX #, Cheng YC #, Zheng M , Yuan BX , Wang ZM, Li XY, Yin J*, Ye MX *, Song Y*. Targeting the ubiquitination/deubiquitination process to regulate immune checkpoint pathways . Signal Transduct Target Ther. 2021 Jan 22;6(1):28.   (18.187    1区)

10. Zhou L#, Xu QL#, Huang LT #, Jin JJ, Zuo XY, Zhang Q, Ye L, Zhu SH, Zhan P, Ren JA*, Lv TF *, Song Y*. Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer. Cancer Lett. 2021 Mar 1;500:163-171.    (8.679     1区)